

May 19, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure of Related Party Transactions for the half year ended 31st March, 2023

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions for the half year / six months ended 31st March, 2023.

The same is also being made available on the website of the Company at www.glenmarkpharma.com

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

357	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Investment	Not Applicable	6,825.93	23,995.00	30,220.93											
358	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Interest Income	Not Applicable	61.11													
359	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Other Income	Not Applicable	579.85													
360	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Receivable	Not Applicable		1,836.27	113.23											
361	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Investment	Not Applicable		19.84	19.84											
362	Ichnos Sciences Inc.	Ichnos Sciences SA	Fellow Subsidiary	Payable	Not Applicable		1.34	1.54											
363	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Payable	Not Applicable		2.31	2.62											
364	Ichnos Sciences Inc.	Ichnos Sciences Biotherapeutics SA	Fellow Subsidiary	Expense Incurred	Not Applicable		2.60												
365	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Other Income	Not Applicable	1,361.33													
366	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Receivable	Not Applicable		765.83	1,340.15											
367	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Payable	Not Applicable		0.60	3.97											
368	Ichnos Sciences Biotherapeutics SA	Ichnos Sciences SA	Fellow Subsidiary	Expense reimbursed	Not Applicable	3.29													
369	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan given	Not Applicable		-	33.19											
370	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan given	Not Applicable	32.09													
371	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	loan repaid	Not Applicable	1.24													
372	Glenmark Pharmaceuticals Inc.	Glenmark Therapeutics Inc.	Fellow Subsidiary	Interest Income	Not Applicable	0.32													

1 All Related Party Transactions entered during the period were in ordinary course of the business and on an arm's length basis.

2 Expenses for Defined Benefit Plans and Compensated Absences are provided on an actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.

3 Share Based Payment Expenses pertaining to Key Managerial Personnel is not included.

4 Balances have been aggregated entity wise for all type of transactions and shown as net receivable/payable

5 As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.

6 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors, as applicable, for financial year 2022-23.

7 All transactions in foreign currency, wherever applicable, have been converted and disclosed in INR.

8 Difference in opening and closing balances is on account of exchange rate fluctuation.

9 All figures in this disclosure are rounded off up to two decimals.